Characteristics of Invasive Cribriform Carcinoma.

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2024-09-01 Epub Date: 2024-07-26 DOI:10.1080/07357907.2024.2383930

Ryusei Yoshino, Masaki Nakatsubo, Nanami Ujiie, Akane Ito, Nana Yoshida, Masahiro Kitada

引用次数: 0

Abstract

Invasive cribriform carcinoma (ICC) is a type of malignant tumor with slow growth and good prognosis. The study was a single center retrospective study. The percentage of ICC among patients diagnosed with breast cancer was 0.3% (8/2454 patients). All patients tested positive for estrogen or progesterone receptors and 12.5% (1/8) patients tested positive for human epidermal growth factor receptor type2 (HER2). The present study suggests that the clinicopathological features of ICC are low-grade hormone receptor-positive luminal type with a good prognosis. However, some patients were HER2-positive and require careful follow-up.

查看原文本刊更多论文

浸润性楔形细胞癌的特征

浸润性楔形细胞癌（ICC）是一种生长缓慢、预后良好的恶性肿瘤。该研究是一项单中心回顾性研究。在确诊的乳腺癌患者中，ICC的比例为0.3%（8/2454例）。所有患者的雌激素或孕激素受体检测均呈阳性，12.5%（1/8）的患者人表皮生长因子受体2型（HER2）检测呈阳性。本研究表明，ICC的临床病理特征为低级别激素受体阳性管腔型，预后良好。然而，部分患者为 HER2 阳性，需要仔细随访。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.